Molecular mechanisms of PARP inhibitors In BRCA-related ovarian cancer

Journal of Cancer Science and Therapy

Volumn 5, Issue 11, 2013, Pages 409-416

  Toss, A ^a   Laura, Cortesi ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Base excision repair; BRCA; DNA damage; Homologous recombination; Ovarian cancer; PARP inhibitors

Indexed keywords

B RAF KINASE; BETA CATENIN; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BUPARLISIB; CARBOPLATIN; CEDIRANIB; CHECKPOINT KINASE 2; DNA DIRECTED DNA POLYMERASE BETA; INIPARIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE NUCLEOSIDASE; NIRAPARIB; OLAPARIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; RAD51 PROTEIN; RUCAPARIB; UNCLASSIFIED DRUG; VELIPARIB;

APOPTOSIS; CLINICAL PRACTICE; DNA DAMAGE; DNA REPAIR; EXCISION REPAIR; FAMILIAL CANCER; HOMOLOGOUS RECOMBINATION; HUMAN; MOLECULAR DYNAMICS; ONCOGENE; OVARY CANCER; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; TUMOR SUPPRESSOR GENE;

EID: 84891512397     PISSN: None     EISSN: 19485956     Source Type: Journal    
DOI: 10.4172/1948-5956.1000234     Document Type: Review

References (59)

1. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, et al. (2012) Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62: 220-241.
2. Han ES, Lin P, Wakabayashi M (2009) Current status on biologic therapies in the treatment of epithelial ovarian cancer. Curr Treat Opt Oncol 10: 54-66.
3. Markman M (2008) Pharmaceutical management of ovarian cancer: Current status. Drugs 68: 771-789.
4. Burges A, Schmalfeldt B (2011) Ovarian cancer: Diagnosis and treatment. Dtsch Arztebl Int 108: 635-641.
5. Thigpen T (2012) A rational approach to the management of recurrent or persistent ovarian carcinoma. Clin Obstet Gynecol 55: 114-130.
6. Toss A, De Matteis E, Rossi E, Casa LD, Iannone A, et al. (2013) Ovarian cancer: can proteomics give new insights for therapy and diagnosis? Int J Mol Sci 14: 8271-8290.
7. Marquez RT, Baggerly KA, Patterson AP, Liu J, Broaddus R, et al. (2005) Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res 11: 6116-6126.
8. Kurman RJ, Shih IeM (2011) Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol 42: 918-931.
9. Bast RC Jr, Hennessy B, Mills GB (2009) The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9: 415-428.
10. Liliac L, Amalinei C, Balan R, Grigoras A, Caruntu ID (2012) Ovarian cancer: insights into genetics and pathogeny. Histol Histopathol 27: 707-719.
11. Kurman RJ, Shih IeM (2008) Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 27: 151-160.
12. Wooster R, Weber BL (2003) Breast and ovarian cancer. N Engl J Med 348: 2339-2347.
13. Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, et al. (2002) Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94: 1365-1372.
14. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE (1994) Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 343: 692-695.
15. Breast Cancer Linkage Consortium (1999) Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91: 1310-1316.
16. Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, et al. (2006) Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295: 1379-1388.
17. Casadei S, Norquist BM, Walsh T, Stray S, Mandell JB, et al. (2011) Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Res 71: 2222-2229.
18. Engel NJ, Gordon P, Thull DL, Dudley B, Herstine J, et al. (2012) A multidisciplinary clinic for individualizing management of patients at increased risk for breast and gynecologic cancer. Fam Cancer 11: 419-427.
19. Cortesi L, Toss A, De Matteis E (2013) Preventive strategies for ovarian cancer. InTech-Open pubblications 1030-1039.
20. Chambon P, Weill Jd, Mandel P (1963) Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem Biophys Res Commun 11: 39-43.
21. Durkacz BW, Omidiji O, Gray DA, Shall S (1980) (ADP-ribose)n participates in DNA excision repair. Nature 283: 593-596.
22. De Vos M, Schreiber V, Dantzer F (2012) The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. Biochem Pharmacol 84: 137-146.
23. Weil MK, Chen AP (2011) PARP inhibitor treatment in ovarian and breast cancer. Curr Probl Cancer 35: 7-50.
24. Li K, Li W (2013) Association between polymorphisms of XRCC1 and ADPRT genes and ovarian cancer survival with platinum-based chemotherapy in Chinese population. Mol Cell Biochem 372: 27-33.
25. Venkitaraman AR (2003) A growing network of cancer-susceptibility genes. N Engl J Med 348: 1917-1919.
26. Gudmundsdottir K, Ashworth A (2006) The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 25: 5864-5874.
27. Orelli BJ, Bishop DK (2001) BRCA2 and homologous recombination. Breast Cancer Res 3: 294-298.
28. Zhang J (2013) The role of BRCA1 in homologous recombination repair in response to replication stress: significance in tumorigenesis and cancer therapy. Cell Biosci 3: 11.
29. Lieber MR, Gu J, Lu H, Shimazaki N, Tsai AG (2010) Nonhomologous DNA end joining (NHEJ) and chromosomal translocations in humans. Subcell Biochem 50: 279-296.
30. Ashworth A (2008) A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA doublestrand break repair. J Clin Oncol 26: 3785-3790.
31. Kruse V, Rottey S, De Backer O, Van Belle S, Cocquyt V, et al. (2011) PARP inhibitors in oncology: a new synthetic lethal approach to cancer therapy. Acta Clin Belg 66: 2-9.
32. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, et al. (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434: 913-917.
33. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, et al. (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917-921.
34. Chionh F, Mitchell G, Lindeman GJ, Friedlander M, Scott CL (2011) The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions. Asia Pac J Clin Oncol 7: 197-211.
35. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, et al. (2009) Inhibition of poly(ADPribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361: 123-134.
36. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, et al. (2010) Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 28: 2512-2519.
37. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, et al. (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376: 245-251.
38. Ledermann JA (2011) Phase II randomized placebo controlled study of olaparib (AZD2281) in patients with platinum sensitive relapsed serous ovarian cancer (PSRSOC). J Clin Oncol.
39. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, et al. (2012) Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366: 1382-1392.
40. Gelmon KA, Hirte HW, Robidoux A, Tonkin KS, Tischkowitz M, et al. (2010) Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous cancer and triple negative breast cancer. J Clin Oncol 28: 18.
41. Kaye SB, Lubinski J, Matulonis U, Ang JE, Gourley C, et al. (2012) Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 30: 372-379.
42. Konstantinopoulos PA, Cannistra SA (2012) Comparing poly (ADP-ribose) polymerase inhibitors with standard chemotherapy in BRCA-mutated, recurrent ovarian cancer: lessons learned from a negative trial. J Clin Oncol 30: 347-350.
43. Yang D, Khan S, Sun Y, Hess K, Shmulevich I, et al. (2011) Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 306: 1557-1565.
44. Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, et al. (2008) Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451: 1116-1120.
45. Kummar S, Ji J, Morgan R, Lenz HJ, Puhalla SL, et al. (2012) A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin Cancer Res 18: 1726-1734.
46. Liu JF, Tolaney SM, Birrer M, Fleming GF, Buss MK, et al. (2013) A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer 49: 2972-2978.
47. Penson RT, Whalen C, Lasonde B, Krasner CN, Konstantinopoulos P, et al. (2011) A phase II trial of iniparib (BSI-201) in combination with gemcitabine/ carboplatin (GC) in patients with platinum-sensitive recurrent ovarian cancer. J Clin Oncol 29: 2011.
48. Birrer MJ, Konstantinopoulos P, Penson RT, Roche M, Ambrosio A, et al. (2011) A phase II trial of iniparib (BSI-201) in combination with gemcitabine/ carboplatin (GC) in patients with platinum-resistant recurrent ovarian cancer. J Clin Oncol 29: 2011.
49. Lee J, Annunziata CM, Hays JL, Noonan AM, Minasian LM, et al. (2013) Phase I/Ib study of the PARP inhibitor olaparib (O) with carboplatin (C) in BRCA1/2 mutation carriers with breast or ovarian cancer (Br/OvCa) (NCT00647062). J Clin Oncol 31.
50. Barazzuol L, Jena R, Burnet NG, Meira LB, Jeynes JC, et al. (2013) Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma. Radiat Oncol 8: 65.
51. Porcelli L, Quatrale AE, Mantuano P, Leo MG, Silvestris N, et al. (2013) Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity. Mol Oncol 7: 308-322.
52. Chow JP, Man WY, Mao M, Chen H, Cheung F, et al. (2013) PARP1 Is Overexpressed in Nasopharyngeal Carcinoma and Its Inhibition Enhances Radiotherapy. Mol Cancer Ther 12: 2517-2528.
53. Senra JM, Telfer BA, Cherry KE, McCrudden CM, Hirst DG, et al. (2011) Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft. Mol Cancer Ther 10: 1949-1958.
54. Lee HJ, Yoon C, Schmidt B, Park do J, Zhang AY, et al. (2013) Combining PARP-1 Inhibition and Radiation in Ewing Sarcoma Results in Lethal DNA Damage. Mol Cancer Ther 12: 2591-2600.
55. Shelton JW, Waxweiler TV, Landry J, Gao H, Xu Y, et al. (2013) In vitro and in vivo enhancement of chemoradiation using the oral PARP inhibitor ABT-888 in colorectal cancer cells. Int J Radiat Oncol Biol Phys 86: 469-476.
56. Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, et al. (2013) The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol 14: 882-892.
57. Ihnen M, zu Eulenburg C, Kolarova T, Qi JW, Manivong K, et al. (2013) Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer. Mol Cancer Ther 12: 1002-1015.
58. http://clinicaltrials.gov/
59. Chiarugi A (2012) A snapshot of chemoresistance to PARP inhibitors. Trends Pharmacol Sci 33: 42-48.